Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis
Digestive and Liver Disease · 2025-05 · 57 (5) · 943-953
DOI: 10.1016/j.dld.2025.01.189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2025-05. Verfasst von Qingqing Dai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, 07747, Jena, Thuringia, Germany. Hauptthemen laut MEDLINE: Endothelial Cells, Liver, Fatty Liver. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kroner-Fresenius Foundation.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the predominant liver disease and is becoming the paramount contributor to end-stage liver disease and liver-related deaths. Liver sinusoidal endothelial cells (LSECs) located between the hepatic parenchyma and blood from viscera and gastrointestinal tract are the gatekeepers for the hepatic microenvironment and normal function. In normal physiological conditions, LSECs govern the substance exchange between hepatic parenchyma and blood through dynamic regulation of fenestration and maintain the quiescent state of Kupffer cells (KCs) and hepatic stellate cells. In MASLD, lipotoxicity, insulin resistance, gastrointestinal microbiota dysbiosis, and mechanical compression caused by fat-laden hepatocytes result in LSECs capillarization and dysfunction. The altered LSECs progressively shift from healer to injurer, exacerbating liver inflammation and advancing liver fibrosis. This review focuses on the deteriorative roles of LSECs and related molecular mechanisms involved in MASLD and their contribution to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis development and progression. Furthermore, in this review, we propose that targeting LSECs dysfunction is a prospective therapeutic strategy to restore the physiological function of LSECs and mitigate MASLD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, 07747, Jena, Thuringia, Germany.
- Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, 07747, Jena, Thuringia, Germany. Electronic address: Alexander.Zipprich@med.uni-jena.de.
Förderung
- Else Kroner-Fresenius Foundation
Zitieren
APA
Dai, Q., Ain, Q., Seth, N., Rooney, M., & Zipprich, A. (2025). Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis. Digestive and Liver Disease, 57(5), 943-953. https://doi.org/10.1016/j.dld.2025.01.189
Vancouver
Dai Q, Ain Q, Seth N, Rooney M, Zipprich A. Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis. Digestive and Liver Disease. 2025;57(5):943-953. doi:10.1016/j.dld.2025.01.189
BibTeX
@article{Dai2025,
author = {Dai, Qingqing and Ain, Quratul and Seth, Navodita and Rooney, Michael and Zipprich, Alexander},
title = {Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis},
journal = {Digestive and Liver Disease},
year = {2025},
volume = {57},
number = {5},
pages = {943--953},
doi = {10.1016/j.dld.2025.01.189}
}
EUVIMED